Here's a classic biotech puzzle: a company announces promising clinical trial data for a serious disease, and the stock goes down. Welcome to the world of Regenxbio Inc. (RGNX), which released new interim results for its Duchenne muscular dystrophy gene therapy on Wednesday. The data looked good—patients were walking better, their hearts were stable—but shares dropped anyway. Sometimes the market reacts to what you didn't say, or to the broader context, more than to the numbers themselves.
The latest readout from the Phase 1/2 AFFINITY DUCHENNE trial of RGX-202 showed that patients receiving the pivotal dose improved by an average of +4.9 points on the North Star Ambulatory Assessment. That's a test that measures functional motor abilities—things like standing up, walking, climbing stairs. For context, Duchenne is a progressive disease, so these patients would typically be getting worse, not better. Beating expected disease progression by nearly five points is a meaningful signal. The therapy also showed cardiac stability, which is crucial because heart complications are a major cause of mortality in Duchenne.
So why is the stock down? Well, biotech investing is a game of expectations and timelines. The company said it expects to share topline pivotal data in the early second quarter of 2026 and plans to request a pre-BLA meeting with the FDA in mid-2026. That's not exactly around the corner. Investors might be weighing this longer pathway against the recent regulatory headwind the company faced: in February, the FDA issued a Complete Response Letter for its other gene therapy, RGX-121, for Hunter syndrome. That's a separate program, but it reminds everyone that regulatory approval is never a given.
On the biomarker front, the data continues to look solid. Microdystrophin expression—a key measure of whether the therapy is delivering the needed protein—remained high and consistent across 13 patients. One new patient, aged 3.6 at dosing, showed expression of 51.2% at week 12. That's encouraging for the therapy's mechanism of action.
Let's talk about the stock itself, because the price action tells its own story. Technically, Regenxbio is in a bit of a tug-of-war. It's trading 7.5% above its 20-day simple moving average but 22.6% below its 100-day average, which suggests it's having trouble sustaining longer-term momentum. Over the past 12 months, shares are up 52%, but they're currently closer to their 52-week lows than highs. The RSI sits at 51.63, right in neutral territory, while the MACD is showing bullish momentum. Put it all together, and you get mixed signals—which might explain why traders aren't rushing in.
Key resistance sits at $9.50, with support at $7.50. As of publication, the stock was down 4.44% at $9.46.
Analysts, for their part, are still broadly positive but have been trimming their targets. The consensus rating is a Buy with an average price target of $28.70. Recently, HC Wainwright & Co. maintained a Buy but lowered its target to $30 on March 9, and Morgan Stanley kept an Overweight rating but cut its target to $17 on March 6. That kind of action suggests optimism tempered by realism.
The bottom line? Regenxbio's Duchenne data is genuinely promising. Improving motor function and stabilizing heart measures in a devastating disease is no small feat. But biotech stocks live in the gap between scientific promise and commercial reality, and right now investors seem focused on the hurdles ahead—the timeline, the regulatory environment, the broader market sentiment—as much as the progress in the clinic. Sometimes good news isn't enough; it has to be perfect. And in biotech, perfect is rare.
